Urolithin A is a gut-derived metabolite produced when certain gut bacteria break down ellagitannins found in pomegranates, walnuts, and berries. It has attracted scientific interest for its ability to trigger mitophagy—the selective removal and recycling of damaged mitochondria—which supports cellular energy and muscle health as we age. As interest in urolithin A supplementation grows, a practical question follows: could it interact with prescription medications or other supplements?
The honest answer is that direct clinical data on urolithin A and drug interactions is very limited. Most research has focused on its mechanisms and safety as a standalone compound. What follows is a careful look at what the evidence does and does not say, including the signaling pathways urolithin A influences and why certain groups may want to exercise particular caution.
Key Takeaways
- Urolithin A activates mitophagy and influences AMPK/SREBP1 signaling—pathways that overlap with the targets of some common medications, including certain diabetes and lipid-lowering drugs.
- Direct clinical data on urolithin A drug interactions does not yet exist; available evidence comes from cell studies and mechanistic research, not human pharmacokinetic trials.
- Urolithin A affects cholesterol-related signaling pathways in laboratory research, which warrants a conversation with a prescriber for anyone on lipid-lowering therapy [1].
- Individual gut metabotype determines how much urolithin A a person produces and how strongly they respond, meaning biological effects—and any interaction risk—are not uniform across people [2].
- Always disclose urolithin A supplementation to your doctor or pharmacist, particularly if you take medications affecting metabolism, mitochondrial function, cholesterol, or immune suppression.
How Urolithin A Works in the Body
Urolithin A’s primary documented mechanism is the activation of mitophagy—a cellular quality-control process that identifies and degrades dysfunctional mitochondria before recycling their components for new mitochondrial biogenesis. This process is important for maintaining healthy muscle mass and physical function, particularly because the efficiency of mitophagy tends to decline with age [3].
By supporting the mitochondrial renewal cycle, urolithin A is thought to help cells maintain adequate energy production. Neurons and glial cells in the brain are especially dependent on well-functioning mitochondria, and mitophagy pathways are therefore of interest in age-related neurological conditions as well [4]. Understanding these mechanisms matters for drug interaction questions because any compound that activates the same cellular pathways as a prescription drug is worth scrutinizing carefully.
Key Signaling Pathways That Could Overlap With Drug Targets
One area of theoretical concern involves the AMPK/SREBP1 signaling axis. Research has shown that urolithin A can attenuate ox-LDL-induced cholesterol accumulation in macrophages partly by modulating miR-33a and activating ERK/AMPK/SREBP1 pathways [1]. AMPK—AMP-activated protein kinase—is a central metabolic sensor and the same enzyme targeted, directly or indirectly, by drugs such as metformin, a widely prescribed type 2 diabetes medication.
This does not mean urolithin A is unsafe alongside metformin. It means the overlap exists at a mechanistic level, and whether the two compounds produce additive, synergistic, or competing effects in humans has not been evaluated in clinical trials. People managing metabolic conditions with prescription medications should be aware of this theoretical overlap and discuss supplementation with their prescribing physician before starting.
Combinatory Exposure: What One Laboratory Study Found
A relevant piece of in vitro evidence comes from a study examining what happens when urolithin A is combined with two common dietary mycotoxins—alternariol and deoxynivalenol, which are fungal contaminants found in some foods. When colon cancer cells were exposed to all three compounds simultaneously, effects on cellular metabolism and epithelial barrier integrity were observed that differed from exposure to any single compound alone [5].
This is not a drug interaction study in the clinical sense—it uses cancer cell lines rather than human subjects, and mycotoxins are not medications. However, the study illustrates a broader principle: urolithin A does not exist in isolation in the body, and its cellular effects can shift when combined with other bioactive compounds. Extrapolating this to human medication use requires significant caution, but the finding supports the general advice to disclose all supplements to a healthcare provider who can consider the full picture.
Individual Variation: Why Gut Metabotype Matters
One underappreciated complexity is that not everyone produces urolithin A from dietary sources in the same amount—or at all. Whether someone is a urolithin A producer depends heavily on the composition of their gut microbiome. Research classifies people into different metabotypes based on which urolithin metabolites they generate, and these categories influence how significantly a person responds to ellagitannin-rich foods or precursor supplements [2].
A randomised, placebo-controlled crossover trial in postmenopausal women found that polyphenol supplementation effects on TMAO—a gut-derived cardiovascular marker—were meaningfully modulated by urolithin A metabotype status [6]. This means the biological activity of urolithin A, and therefore any potential interactions with medications, may vary substantially between individuals based on gut microbiome composition. This is important context for anyone whose gut microbiome has been altered by antibiotics, gastrointestinal conditions, or medications that affect gut flora.
Medication Categories That May Warrant Extra Caution
While no human clinical trials have specifically mapped urolithin A drug interactions, several pharmacological categories are worth flagging based on mechanistic overlap. Lipid-lowering medications such as statins affect cholesterol metabolism via pathways that may intersect with urolithin A’s documented effects on the AMPK/SREBP1 axis and macrophage cholesterol handling [1]. This does not imply harm, but the mechanistic proximity is a conversation worth initiating with a prescriber.
Drugs that affect mitochondrial function—whether intentionally or as a known side effect—are another area of theoretical consideration. Certain antibiotics, antiretroviral medications, and some chemotherapy agents can impair mitochondrial function. Since urolithin A works by enhancing mitochondrial quality control via mitophagy, there is a plausible biological rationale for discussing its use alongside drugs with documented mitochondrial effects [3].
Immunosuppressant medications also warrant mention. Although none of the provided studies specifically address this combination, urolithin A affects intracellular signaling pathways involved in cellular autophagy and proliferation. Anyone taking immunosuppressants following an organ transplant or for an autoimmune condition should consult their specialist before adding any new supplement to their routine.
What the Research Does Not Yet Tell Us
It is important to be direct about the gaps. There are no published randomised controlled trials specifically designed to assess urolithin A’s pharmacokinetic or pharmacodynamic interactions with specific prescription drugs in humans. Most mechanistic data comes from cell culture or animal studies, and translation to clinical drug interactions cannot be assumed without dedicated human research.
The available evidence—including studies on mitophagy, AMPK signaling, and combinatory cellular exposure—is scientifically informative but not definitive on the question of drug interactions in clinical practice [5][1]. Until purpose-designed interaction studies are conducted, the prudent approach is to treat urolithin A supplements the way you would any biologically active compound: disclose use to all prescribers, start at low doses if beginning supplementation, and monitor for any unexpected changes in how your medications seem to be working.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day — The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10) — established clinical-supplement brand, third-party tested. - ProHealth Longevity Urolithin A
capsules, 500 mg — Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg — Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The evidence base for urolithin A drug interactions in humans is very limited; most mechanistic findings come from cell culture or animal studies and cannot be directly applied to clinical medication management. If you take prescription medications—particularly those affecting metabolism, cholesterol, mitochondrial function, or immune suppression—consult your doctor or pharmacist before adding urolithin A supplements to your routine. Nothing in this article constitutes medical advice.
Frequently Asked Questions
Can urolithin A be taken with metformin?
There are no human studies directly testing this combination. Both urolithin A and metformin influence AMPK-related metabolic pathways [1], which creates a theoretical mechanistic overlap worth discussing with a prescriber. Until controlled human research is available, anyone taking metformin should raise urolithin A supplementation with their doctor before starting.
Does urolithin A interact with cholesterol-lowering medications?
Urolithin A has been shown in laboratory research to affect cholesterol accumulation in macrophages via the AMPK/SREBP1 signalling pathway [1]. Whether this produces a clinically meaningful interaction with statins or other lipid-lowering drugs in humans has not been studied in clinical trials. Until that data exists, caution and medical consultation are advisable for people on these medications.
Can urolithin A affect how other supplements or dietary compounds work?
Research has shown that when urolithin A is combined with other bioactive compounds in cell culture, the combined effects on cellular metabolism and epithelial barrier function can differ from those of any single compound alone [5]. This principle likely extends to complex supplement combinations, though human data to quantify such interactions does not currently exist.
Does gut health affect how urolithin A interacts with medications?
Gut metabotype significantly shapes how much urolithin A a person produces and how they respond to polyphenol intake [2][6]. Medications or conditions that alter the gut microbiome—such as antibiotics, proton pump inhibitors, or inflammatory bowel disease—could change someone’s urolithin A metabotype and therefore the magnitude of its biological activity and any theoretical interactions.
Is urolithin A relevant for people on neurological medications?
Urolithin A supports mitophagy, a process that is particularly important for the health of neurons and glial cells, which are highly dependent on functional mitochondria [4]. Research is exploring its potential relevance to neurological health, but there are currently no clinical studies examining interactions with neurological medications such as those used for Parkinson’s disease, epilepsy, or dementia.
Should I inform my doctor or pharmacist that I am taking urolithin A?
Yes. Although dedicated drug interaction studies in humans are currently lacking, urolithin A influences biologically meaningful signaling pathways and its effects can vary based on individual gut microbiome composition [2]. Disclosing all supplements—including urolithin A—to your prescribing physician and pharmacist allows them to consider the full picture of what you are taking and flag any concerns.
References
- Han QA et al. Urolithin A attenuated ox-LDL-induced cholesterol accumulation in macrophages partly through regulating miR-33a and ERK/AMPK/SREBP1 signaling pathways. Food & function (2020). PMID 32236173
- Cortés-Martín A et al. Where to Look into the Puzzle of Polyphenols and Health? The Postbiotics and Gut Microbiota Associated with Human Metabotypes. Molecular nutrition & food research (2020). PMID 32196920
- Broome SC et al. Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function During Ageing. Sports medicine (Auckland, N.Z.) (2024). PMID 39060742
- Kaushik M et al. Mitochondrial Function in Neurons and Glia in Health and Its Alteration in Parkinson's Disease: A Review. Current neuropharmacology (2026). PMID 42163657
- Groestlinger J et al. Combinatory Exposure to Urolithin A, Alternariol, and Deoxynivalenol Affects Colon Cancer Metabolism and Epithelial Barrier Integrity in vitro. Frontiers in nutrition (2022). PMID 35811943
- Jarrín-Orozco MP et al. Precision health targeting TMAO in postmenopausal women: polyphenol effects modulated by urolithin A and equol metabotypes in a randomised, placebo-controlled crossover trial. Food & function (2026). PMID 41642121
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.